José Manuel Pérez-García

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 642 citations · Full text

Medicine, Oncology, Pharmacology +16

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Ana Bosch, Zhiqiang Li, Anna Bergamaschi et al. · Science Translational Medicine · 2015 · 436 citations

Life Sciences, Molecular Biology, Oncology +17

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bédard, Josep Tabernero, Filip Jankú et al. · Clinical Cancer Research · 2014 · 326 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André, Thomas Bachelot, Mario Campone et al. · Clinical Cancer Research · 2013 · 313 citations

Medicine, Oncology, Pharmacology +14